Interferon prophylaxis against simian varicella in Erythrocebus patas monkeys.
Erythrocebus patas monkeys were given placebo or human leukocyte interferon (5 x 10(5) units/kg of body weight per day im) for five days during an epizootic of simian varicella. During the 14 days beginning with the first day of treatment, the attack rate for simian varicella was 14.3% (two of 14) among interferon recipients compared to 70% (nine of 13) among placebo recipients (P less than 0.025). Excluding animals with antibody to simian varicella when the study began, 18% (two) of 11 interferon recipients had symptoms of infection compared to 80% (nine) of 11 placebo recipients (P less than 0.025). The epizootic began in a room housing male animals. The incidence of infection in male placebo recipients was 100% (seven of seven) compared to 14% (one of seven) in male interferon recipients (P less than 0.01). The efficacy of interferon prophylaxis in the simian varicella model supports its continued evaluation for the management of human varicella in high-risk patients.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D004195:Disease Models, Animal; D004901:Erythrocebus patas; D005260:Female; D006562:Herpes Zoster / Q000188:drug therapy / Q000517:prevention & control*; D014645:Herpesvirus 3, Human / Q000276:immunology*; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D010746:Phosphonoacetic Acid / Q000627:therapeutic use
D000914:Antibodies, Viral; D007370:Interferon Type I; D010746:Phosphonoacetic Acid